"Immunohistochemistry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Descriptor ID |
D007150
|
MeSH Number(s) |
E01.370.225.500.607.512 E01.370.225.750.551.512 E05.200.500.607.512 E05.200.750.551.512 E05.478.583 H01.158.100.656.234.512 H01.158.201.344.512 H01.158.201.486.512 H01.181.122.573.512 H01.181.122.605.512
|
Concept/Terms |
Immunolabeling Techniques- Immunolabeling Techniques
- Immunolabeling Technique
- Technique, Immunolabeling
- Techniques, Immunolabeling
- Immunolabeling Technics
- Immunolabeling Technic
- Technic, Immunolabeling
- Technics, Immunolabeling
Immunogold Techniques- Immunogold Techniques
- Immunogold Technique
- Technique, Immunogold
- Techniques, Immunogold
- Immunogold Technics
- Immunogold Technic
- Technic, Immunogold
- Technics, Immunogold
Immunogold-Silver Techniques- Immunogold-Silver Techniques
- Immunogold Silver Techniques
- Immunogold-Silver Technique
- Technique, Immunogold-Silver
- Techniques, Immunogold-Silver
- Immunogold-Silver Technics
- Immunogold Silver Technics
- Immunogold-Silver Technic
- Technic, Immunogold-Silver
- Technics, Immunogold-Silver
|
Below are MeSH descriptors whose meaning is more general than "Immunohistochemistry".
Below are MeSH descriptors whose meaning is more specific than "Immunohistochemistry".
This graph shows the total number of publications written about "Immunohistochemistry" by people in this website by year, and whether "Immunohistochemistry" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 1 | 62 | 63 |
1995 | 1 | 68 | 69 |
1996 | 4 | 59 | 63 |
1997 | 2 | 75 | 77 |
1998 | 0 | 85 | 85 |
1999 | 1 | 101 | 102 |
2000 | 1 | 96 | 97 |
2001 | 1 | 109 | 110 |
2002 | 2 | 113 | 115 |
2003 | 6 | 234 | 240 |
2004 | 1 | 235 | 236 |
2005 | 2 | 260 | 262 |
2006 | 3 | 198 | 201 |
2007 | 6 | 186 | 192 |
2008 | 8 | 191 | 199 |
2009 | 9 | 179 | 188 |
2010 | 7 | 179 | 186 |
2011 | 4 | 212 | 216 |
2012 | 7 | 174 | 181 |
2013 | 6 | 148 | 154 |
2014 | 6 | 161 | 167 |
2015 | 9 | 151 | 160 |
2016 | 7 | 122 | 129 |
2017 | 9 | 102 | 111 |
2018 | 11 | 63 | 74 |
2019 | 5 | 76 | 81 |
2020 | 9 | 53 | 62 |
2021 | 6 | 43 | 49 |
2022 | 0 | 21 | 21 |
2023 | 1 | 14 | 15 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunohistochemistry" by people in Profiles.
-
Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) Immunohistochemistry Can Be a Useful Ancillary Tool to Identify Perivascular Epithelioid Cell Tumor. Mod Pathol. 2024 Mar; 37(3):100426.
-
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation. Diagn Pathol. 2024 Jan 10; 19(1):10.
-
In ER-Positive, HER2-Negative Breast Cancers, HER2 mRNA Levels Correlate Better with Clinicopathologic Features and Oncotype DX Recurrence Score than HER2 Immunohistochemistry. Lab Invest. 2024 03; 104(3):100309.
-
SOX11+ Large B-Cell Neoplasms: Cyclin D1-Negative Blastoid/Pleomorphic Mantle Cell Lymphoma or Large B-Cell Lymphoma? Mod Pathol. 2024 Feb; 37(2):100405.
-
Deep Learning-Based H-Score Quantification of Immunohistochemistry-Stained Images. Mod Pathol. 2024 Feb; 37(2):100398.
-
TRPS1 expression in primary and secondary extramammary Paget diseases: An immunohistochemical analysis of 93 cases. Hum Pathol. 2024 Jan; 143:5-9.
-
HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol. 2023 11; 34(11):1035-1046.
-
Unsupervised domain adaptation for nuclei segmentation: Adapting from hematoxylin & eosin stained slides to immunohistochemistry stained slides using a curriculum approach. Comput Methods Programs Biomed. 2023 Nov; 241:107768.
-
Discordance of HER2 Expression and/or Amplification on Repeat Testing. Mol Cancer Ther. 2023 Aug 01; 22(8):976-984.
-
PD-L1 (22C3) Expression Correlates with Clinical and Molecular Features of Lung Adenocarcinomas in Cytological Samples. Acta Cytol. 2023; 67(5):507-518.